Surescripts, which is being sued by FTC over alleged e-prescription monopoly, says that a contractor, ReMy Health, illegally gave its data to Amazon's PillPack
Christina Farr / CNBC :
Context & Ripple Effects
Surescripts sits at the center of a two-front fight. The FTC is suing it over an alleged e-prescription monopoly, and now the network itself accuses its own contractor ReMy Health of illegally feeding its data to PillPack — the pharmacy Amazon bought in 2018 to attack CVS and Walgreens in a $500B-a-year prescription market, per CNBC's inside account of the acquisition.
The accusation lands mid-battle: PillPack is already clashing with CVS and Walgreens, who claim it requests prescription transfers without patient consent (that transfer fight), and weeks later Surescripts moves to cut ReMy Health off entirely, throttling PillPack's access to patient medication histories.
First-order effects
- Surescripts, while defending the FTC's monopoly suit, gains a narrative counterpunch — casting itself as the victim of data theft rather than a gatekeeper — while ReMy Health faces breach-of-contract and legal exposure from its own principal.
- PillPack's pipeline of patient medication histories through ReMy Health is immediately in legal jeopardy, threatening the data advantage it needs against CVS and Walgreens.
Second-order effects
- Surescripts can weaponize its network position — and did, severing ReMy Health weeks later — turning e-prescription data access into a competitive lever against Amazon's pharmacy push at the same moment incumbents are fighting PillPack on transfers.
- The FTC's dual posture — prosecuting Surescripts as a monopolist while separately policing health-data sharing, as in its $1.5M GoodRx settlement over data handed to Meta and Google — pressures every intermediary in the pharmacy data chain to tighten contractor controls.
Third-order effects
- If the pattern holds, control of patient-data plumbing becomes the decisive chokepoint in US pharmacy competition, with whoever operates the e-prescription rails able to advantage or starve entrants — the exact conduct the FTC's suit is testing.
- Online pharmacy consolidation continues around scaled players — UnitedHealth's $300M+ DivvyDose acquisition folded another PillPack competitor into an insurer — raising the stakes of who controls the data layer beneath them.
The trend: As Amazon's PillPack challenges incumbent pharmacies, the e-prescription data layer is becoming the contested chokepoint that will shape who can compete in US drug retail.